share_log

Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $38

Benzinga ·  May 9 13:45

Citigroup analyst David Lebovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $37 to $38.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment